Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Deciphering the role of the CD47 Immune Checkpoint in Immunotherapy Resistance in High-Grade Serous Ovarian Carcinoma

FY 2023-24

Summary
High-grade serous ovarian carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer with a 5-year survival rate of 29%. Additionally, 70-95% of patients with late-stage HGSC have recurrence, making HGSC the leading cause of gynecological cancer-related deaths in the developed world. Immunotherapy, a type of treatment that activates the immune system to fight cancer, has limited efficacy in HGSC. We propose that the heterogenous tumor microenvironment (TME) and expression of specific protein markers on the malignant cells may limit the potency of immunotherapy in these patients. We aim to understand the regulation and role of one of these markers called CD47, also known as the "don't eat me signal", that is enriched in HGSC compared to non-malignant fallopian tube samples on single-cell sequencing. Our analysis also predicted increased secretion of another protein called Thrombospondin (THBS) by cancer-associated fibroblasts (CAFs) found in the stroma of HGSC, which is known to regulate CD47. We hypothesize that crosstalk between CAFs, immune cells, and CD47-expressing tumor cells promotes the immunosuppressive TME in HGSC and that depletion of CD47 will improve anti-tumor immune activation. To test this hypothesis, we will first use genome editing of potential CD47 regulators to characterize how CD47 is expressed. Using a microfluidic device (MFD) based co-culturing system I will grow tumor-derived spheroids with immune cells and identify the cell subtypes most affected by the loss of CD47 by gene expression. Second, using a MFD that allows us to preserve the TME by growing cancer tissue removed from patients during surgery, I will test how depletion of THBS-secreting CAFs and targeting the transcriptional regulators upstream of CD47 influences response to immunotherapy. Our work will provide novel insight into the TME of HGSC and contribute to much-needed progress in treating this lethal disease via combination immunotherapy approaches.
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Location
Minnesota, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
495511
Name
Dumbrava Mihai G
Region
Minnesota
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Deciphering the role of the CD47 Immune Checkpoint in Immunotherapy Resistance in High-Grade Serous Ovarian Carcinoma
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Immune Checkpoints; Immunotherapy; Microfluidics; Multi-Omics; Ovarian Cancer; Tumor Microenvironment
Abstract
High-grade serous ovarian carcinoma (HGSC) is the most common and deadly subtype of ovarian cancer with a 5-year survival rate of 29%. Additionally, 70-95% of patients with late-stage HGSC have recurrence, making HGSC the leading cause of gynecological cancer-related deaths in the developed world. Immunotherapy, a type of treatment that activates the immune system to fight cancer, has limited efficacy in HGSC. We propose that the heterogenous tumor microenvironment (TME) and expression of specific protein markers on the malignant cells may limit the potency of immunotherapy in these patients. We aim to understand the regulation and role of one of these markers called CD47, also known as the "don't eat me signal", that is enriched in HGSC compared to non-malignant fallopian tube samples on single-cell sequencing. Our analysis also predicted increased secretion of another protein called Thrombospondin (THBS) by cancer-associated fibroblasts (CAFs) found in the stroma of HGSC, which is known to regulate CD47. We hypothesize that crosstalk between CAFs, immune cells, and CD47-expressing tumor cells promotes the immunosuppressive TME in HGSC and that depletion of CD47 will improve anti-tumor immune activation. To test this hypothesis, we will first use genome editing of potential CD47 regulators to characterize how CD47 is expressed. Using a microfluidic device (MFD) based co-culturing system I will grow tumor-derived spheroids with immune cells and identify the cell subtypes most affected by the loss of CD47 by gene expression. Second, using a MFD that allows us to preserve the TME by growing cancer tissue removed from patients during surgery, I will test how depletion of THBS-secreting CAFs and targeting the transcriptional regulators upstream of CD47 influences response to immunotherapy. Our work will provide novel insight into the TME of HGSC and contribute to much-needed progress in treating this lethal disease via combination immunotherapy approaches.
Competitiondate
202310
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Dumbrava, Mihai G
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2023-24) | Canada Spends